Drug intelligence / Profile preview

SER-190

Development stage: Unknown
Lead developer: Serina Therapeutics
Modality: Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Subcutaneous

Overview

SER-190 is a polymer-drug conjugate consisting of the dopamine agonist rotigotine covalently linked to a poly(2-oxazoline) (POZ) polymer. Developed by Serina Therapeutics, it is designed as a long-acting subcutaneous injection for the treatment of Parkinson's disease. The POZ platform enables a controlled release of rotigotine, aiming to provide continuous dopaminergic stimulation (CDS) and maintain stable plasma levels, thereby reducing the motor fluctuations and dyskinesia associated with pulsatile dopaminergic therapy. By utilizing a weekly dosing schedule, SER-190 seeks to improve patient compliance and therapeutic outcomes compared to daily transdermal patches or oral medications.

Other names: POZ-rotigotinePoly(2-oxazoline) rotigotine

Beyond the preview

Go deeper on SER-190.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-190.